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I. Introduction 
 
Through a Board of Pharmacy, the State of Maine licenses and regulates the activities of 
pharmacists, pharmacy technicians, drug outlets (pharmacies), manufacturers and 
wholesalers in the distribution, delivery and dispensing of prescription drugs.  The purpose 
of the Board and all licensing entities established by the Maine Legislature is to protect the 
health, safety and welfare of Maine citizens.  The board meets its public protection 
mandate through examination and licensing of applicants who meet minimum licensing 
standards and by imposing discipline on licensees who fail to meet licensing, and state and 
federally recognized practice and safety standards. 
 
II. Intent of LD 1827 
 
During the 122nd Maine Legislature, Representative Judd Thompson submitted a bill, L.D. 
1827, entitled “An Act to Clarify Prescription Drug Labels,” which became Resolve 
Chapter 138 entitled “Resolve, Directing the Department of Professional and Financial 
Regulation to Study Prescription Drug Labeling Requirements.”  This resolve was signed 
by the Governor on March 17, 2006 and took effect on August 23, 2006.  
 
III. Charge from the Legislature 
 
The resolve called on the Department of Professional and Financial Regulation (“the 
Department”) to consider: 
 
A. …current statutory requirements for prescription drug 
labeling; and 
B. …pharmacy practices in the area of prescription drug 
labeling and the methods used by pharmacists to inform 
consumers about their prescription drugs and any substitutions 
made to prescriptions; … 
 
IV. Study Process 
 
Following the enactment of L.D. 1827, the Department developed a working group with   
expertise in the areas of pharmacist regulation and retail pharmacy operations.  
Participating members of the working group were: 
 
Paul Chace, R.Ph.  
 Pharmacist Member of the Board of Pharmacy and the Board’s Complaint Officer  
John Harris 
 Public Member of the Board of Pharmacy 
Ken Fasulo 
 Representative from Hannaford Bros. Co. – Chain Pharmacies 
Douglas Carr, Esq., 
 Rite Aid Pharmacies – Participation through report preparation review 
Robert Morrissette, R.Ph. 
 Executive Director, Maine Pharmacy Association – Due to scheduling conflicts declined 
invitation to participate 
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Anne L. Head 
 Director, Office of Licensing and Registration   
Geraldine L. Betts 
 Board Administrator, Office of Licensing and Registration   
  
The working group met at the Department’s offices in Gardiner, Maine on August 21, 
2006 and completed its final report review via email communications. 
 
Preparing and dispensing prescription drugs is regulated by laws enacted by the Maine 
Legislature, rules adopted by the Maine Board of Pharmacy and Title 21 of the Code of 
Federal Regulations (“CFR”) on drug enforcement. 
 
The work group studied applicable laws and regulations on prescription drug labeling.  See 
Appendix A for a comparison of federal and state prescription drug labeling requirements.     
 
V. Issues Raised 
 
1) Overlapping directives regarding  labeling requirements 
 
The work group agreed that the needs and demands for information on a prescription label 
are difficult, if not impossible, to satisfy.  The size of containers and labels, coupled with 
current federal and state requirements for information on prescription labels, limits 
customization.   
 
The group recognized the need to provide factual and reliable information to consumers for 
safe and appropriate administration of prescribed medication.    
 
Ken Fasulo manages the technical aspects of periodically updating pharmacy labeling and 
printing needs for Hannaford pharmacies.  Mr. Fasulo reported that Hannaford is currently 
reviewing its labeling information to insure that federal and state labeling mandates are 
met and required information is current.  Mr. Fasulo also pointed out that Hannaford has 
pharmacies in eleven states and tries to customize the requirement of each state to the 
extent possible.  Currently, the following information is listed on Hannaford labels: 
   
    Rx number 
PH address/phone 
Dr Name 
Patient name   
Dispensing date – fill date 
Patient address – optional privacy issue ( 6 font- confirmation/identification) 
Drug name –  
Manufacturer  
Prescriber – phone  
Discard after date 
NDC number 
Pharmacist full name (initials at a minimum) 
 
At times, the font size on a label is extremely small in order to fit all required information 
on a single label (note Ariel 6 point font above).  In many instances, the font is so small that consumers 
report having difficulty reading the information.   Cautionary stickers regarding the 
appropriate use and storage of medication take up additional space on labels and 
containers.  These stickers are required by the federal Food and Drug Administration 
(FDA) and are critical to patient safety.   
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2) Patient fact sheet 
 
In addition to information on a prescription label, each dispensed medication must include 
a prescription information fact sheet.  The information on the fact sheet is comprehensive 
and intended to educate the patient.  At a minimum, it contains all required label 
information, a listing of common uses of the medication, instructions for its use and a 
description of possible side effects.  
 
32 MRSA § 13784. Patient information regulation 
 1.  Explanation by pharmacist. With each new prescription dispensed, the 
pharmacist, in addition to labeling the prescription in accordance with the 
requirements of the State, must orally explain to the patient or the patient's agent 
the directions for use and any additional information, in writing if necessary, to 
assure the proper utilization of the medication or device prescribed. For those 
prescriptions delivered outside the confines of the pharmacy, the explanation 
shall be by telephone or in writing. This section does not apply to those 
prescriptions for patients in hospitals or institutions where the medication is to 
be administered by a nurse or other individual licensed to administer medications 
or to those prescriptions for patients who are to be discharged from a hospital or 
institution. 
  
Acting Commissioner Head conveyed to the working group that Representative 
Thompson, sponsor of the bill, was responding to a constituent’s need to have the 
“common name” listed on the container label to help the patient or the caregiver identify 
what medication the patient is taking.  The patient had been prescribed several 
medications.   
 
The pharmacist member of the group could not support listing ‘common names’ on the 
label.  He expressed concern that adding another drug name to the label could create 
confusion and jeopardize the information currently required on labels.  In addition, the 
word ‘common’ is not a universally known or defined term in the practice of pharmacy 
and, in some instances, could constitute mis-branding of the prescription when the 
proprietary product is being dispensed.   
 
Working group members indicated that patients and caregivers are typically more familiar 
with brand names than generic names, such as Diazepam, which is also known as Valium.  
The same theory would apply to potassium, which would be difficult to describe given the 
limited space on a container or label.  It was agreed that the appropriate place to fully 
describe the medication is on the patient information “fact sheet,” which is an insert 
required by FDA for all prescription medication dispensed.  A prescriber may verbally 
communicate to a patient that “potassium” is being prescribed, but medication dispensed is 
in accordance with the prescription drug order.   The brand or generic name appears on the 
label.  
 
3) Cost of reconfiguring pharmacy computer systems 
 
A universally recognized computer system is not used among all pharmacies.  For 
example, some independent pharmacies may use the QS1 system, Hannaford and Wal-
Mart use the PDX system, and Rite Aid uses its own specialized system.  Requiring 
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another label change would lead to programming and operating cost increases that would 
be likely be passed on to the purchaser.  Another label change in this situation is 
unnecessary.    
 
4) Role of the prescribing practitioner and the pharmacist 
 
The working group agreed on the importance for the patient or caregiver to talk with the 
prescribing practitioner.  It is the responsibility of the prescribing practitioner to evaluate 
medical conditions, determine medical treatment, and provide information on treatment 
plans to the patient.  A prescribing practitioner may be knowledgeable about 20-40 drugs, 
while a pharmacist is generally knowledgeable of up to 870 drugs on pharmacy shelves.   
  
The pharmacist is prepared to educate and counsel the patient on the pharmacology of the 
dispensed drug.  For each new prescription drug dispensed, the pharmacist must counsel 
the patient on the medication, how to store the medication, and on the frequency and 
proper way to take the medication.  The label includes the initials of the pharmacist 
responsible for the dispensed drug.  Although this may make it difficult for a patient to 
identify the pharmacist who filled the prescription, the pharmacist on duty is always 
prepared to respond to questions.  
 
The pharmacist cannot respond to questions about a doctor’s method on medically related 
treatment and refers the patient to his or her health care provider.  According to working 
group members, a perception exists that people cannot call on a pharmacist for information 
about the prescription drug dispensed.  During normal business hours, all pharmacies have 
a pharmacist on duty to supervise pharmacy activities and to answer questions about 
prescription drugs.  A pharmacy technician cannot respond to pharmacology questions for 
lack of appropriate education and training on pharmacology, patient counseling, and drug 
utilization, but generally can assist with insurance questions.  The patient or caregiver can 
and should ask questions of the pharmacist when needed.   
 
VI. Conclusion 
 
a) Both state and federal regulations identify information that is required on 
prescription bottles and labels.  
 
b)  Currently, the space on prescription bottles and labels is extremely limited.  Any 
additional information will further reduce the font size making it even more difficult for a 
patient to read critical information.  Patients already criticize the font size of current 
information.   
 
c) Reprogramming various computer systems used by pharmacies to meet additional 
information needs would create a cost increase, which would likely be passed on to the 
consumer. 
 
c) The working group agrees that communication with patients and caregivers is 
important for successful medical treatment.  As required by law (32 MRSA §13784) for all new 
prescriptions, the pharmacist accomplishes this task by orally explaining to the patient or 
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the caregiver the directions for use and any additional information to assure the proper 
utilization of the medication or device prescribed. 
  
d) Pharmacists respond to pharmacology questions from patients and caregivers 
regardless of the severe shortage of pharmacists in Maine.  Placing additional and 
unnecessary burdens on pharmacists could reduce the efficacy of services currently 
provided. 
   
e) The working group reached consensus that it is impossible to respond to each 
individual request as it applies to printed information on labels.  It is also noteworthy that 
prescription medication dispensed by an authorized prescriber from his or her office does 
not carry the labeling requirements mandated for prescription medication dispensed from a 
pharmacy.  
 
Based on these factors, the working group is confident that current pharmacology services 
are sufficient to meet patient needs.  The group does not recommend additions or deletions 
on prescription labels from the currently applied standards of practice.       
 
VII. Recommendation for Best Practice 
 
The working group agrees that communication among patients, prescribers and 
pharmacists is critical to educating the patient and the caregiver on prescribed and over-
the-counter medication.  However, legislating communication methods is not always the 
best approach.  A patient or caregiver should be encouraged by health care practitioners to 
ask questions.  Many patients currently ask questions of the pharmacist.  Even mandating 
pharmacies to post signage to encourage a patient or caregiver to contact his or her health 
care provider on questions about treatment, or the pharmacist on pharmacology questions, 
is not a guarantee that the issue at hand would be resolved.  Such action is considered 
unnecessary by the working group.   
 
The working group does recommend that the Board of Pharmacy remind licensed 
pharmacists about the mandatory patient counseling requirements and emphasize the 
importance of encouraging communication to assist patients and caregivers to the extent 
possible and legally allowed.  
 
  Page 6 of 8  
APPENDIX A 
 
CURRENT LABELING REQUIREMENTS 
Code of Federal Regulations and Maine Pharmacy Law and Board Rules 
 
Title 21 Code of Federal Regulations (“CFR”) Labeling Requirements1
Code of Federal Regulations (1306.14) 
 
Minimum required information on the 
prescription label for a controlled substance 
listed in Schedule II: 
 
 
 
Exception:  These requirements do not apply 
when a controlled substance listed in Schedule 
II is prescribed for administration to an ultimate 
user who is institutionalized under certain 
provision, see CFR 1306.14 (c)(1-4) 
    
If filled at a central fill pharmacy:  
 
 
 
 
 
 
3 Date of filling; 
3 Pharmacy name; 
3 Pharmacy address; 
3 Serial number of the prescription; 
3 Name of the patient; 
3 Name of the prescribing practitioner; 
3 Directions for use; and 
3 Cautionary statements, if any. 
 
 
 
 
 
      
In addition to the above – 
3 Retail pharmacy name and address; and 
3 Unique identifier, (i.e. the central fill 
pharmacy’s DEA registration number) 
indicating that the prescription was 
filled at the central pharmacy. 
 
Code of Federal Regulations (1306.24) 
 
Minimum required information on the 
prescription label for a controlled substance 
listed in Schedule III, IV, or V: 
 
 
Exception:  These requirements do not apply 
when a controlled substance listed in Schedule 
II is prescribed for administration to an ultimate 
user who is institutionalized under certain 
provisions, see CFR 1306.14 (c)(1-4) 
      
If filled at a central fill pharmacy:  
 
 
 
 
 
 
3 Date of initial filling; 
3 Pharmacy name; 
3 Pharmacy address; 
3 Serial number of the prescription; 
3 Name of the patient; 
3 Name of the prescribing practitioner 
issuing the prescription; 
3 Directions for use; and 
3 Cautionary statements, if any. 
 
 
 
  
In addition to the above – 
3 Retail pharmacy name and address; and 
3 Unique identifier, (i.e. the central fill 
pharmacy’s DEA registration number) 
indicating that the prescription was 
filled at the central pharmacy. 
 
  
                                                   
1 The labeling requirement in Title 21 § 1306.14 is specific to Schedule II controlled substances only and 
1306.24 is specific to Schedule III, IV and V controlled substances.  With the exception of minor wording 
variations, requirements between the two are relatively the same. 
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Maine Pharmacy Practice Act  
(32 MRSA C.117) 
 
32 MRSA 13702 (12) Labeling. "Labeling" 
means the process of preparing and affixing a 
label to the outside of any drug container, 
exclusive of the labeling by a manufacturer, 
packer or distributor of a nonprescription drug 
or commercially packaged legend drug or 
device. Any such label shall include all 
information required by federal law or 
regulation and state law or rule.  
     
§13794. Labeling of prescriptions 
Every drug dispensed pursuant to prescription, 
whether for a legend drug or not, must carry on 
the label….  
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Board of Pharmacy Rules (Chapter 21, Section 
4 Labeling) 
 
In addition to the information required by 32 
MRSA § 13794, the prescription container 
(label) must clearly show…. 
 
 
  
 
 
Key:  Blue print denotes overlap from CFR 
requirements. 
 
 
 
 
 
 
 
 
 
 
      
3 Prescription number 
3 Date of filling 
3 Patient name 
3 Directions for use 
3 Name and strength of the drug 
3 Amount dispensed, including either the 
brand name of the drug or, if a generic 
and therapeutically equivalent drug is 
dispensed it must be in accordance with 
32 MRSA, § 13781 
3 Beyond use date of the drug (“beyond 
use date” means a date beyond which 
the contents of the prescription are not 
recommended to be used) 
3 Name, address and telephone number of 
the pharmacy where the prescription 
was compounded or dispensed. 
     
 
3 The name and address of the originating 
drug outlet; 
3 The name and address or the unique 
identifier of the central fill drug outlet 
(bar code or symbol acceptable); 
3 Identifying information of the 
originating drug outlet, such as the 
tracking number (bar code or symbol 
acceptable); and 
3 Patient information. 
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